The PE Ratio as of November 2024 (TTM) for Dermata Therapeutics, Inc. (DRMA) is -0.09

According to Dermata Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.09. This represents a change of -92.46% compared to the average of -1.19 of the last 4 quarters.

Dermata Therapeutics, Inc. (DRMA) Historical PE Ratio (quarterly & annually)

How has DRMA PE Ratio performed in the past?

The mean historical PE Ratio of Dermata Therapeutics, Inc. over the last ten years is -70.77. The current -0.09 PE Ratio has changed -87.28% with respect to the historical average. Over the past ten years (40 quarters), DRMA's PE Ratio was at its highest in in the June 2024 quarter at -0.14. The PE Ratio was at its lowest in in the December 2020 quarter at -6544.16.

Dermata Therapeutics, Inc. (DRMA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Dermata Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Dermata Therapeutics, Inc. (DRMA) Average PE Ratio

How has DRMA PE Ratio performed in the past?

The current PE Ratio of Dermata Therapeutics, Inc. (DRMA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Dermata Therapeutics, Inc. (DRMA) PE Ratio vs. Peers

How is DRMA’s PE Ratio compared to its peers?

Dermata Therapeutics, Inc.’s PE Ratio is greater than Zura Bio Limited (-5.60), greater than Phio Pharmaceuticals Corp. (-0.33), greater than Sonnet BioTherapeutics Holdings, Inc. (-1.88), greater than 180 Life Sciences Corp. (-0.71), greater than Cardio Diagnostics Holdings, Inc. (-0.79), less than Windtree Therapeutics, Inc. (-0.03), greater than Ensysce Biosciences, Inc. (-0.54), less than Panbela Therapeutics, Inc. (-0.06), greater than Baudax Bio, Inc. (-0.16), less than ZyVersa Therapeutics, Inc. (-0.00), greater than Revelation Biosciences, Inc. (-0.13), less than Navidea Biopharmaceuticals, Inc. (0.03), less than Altamira Therapeutics Ltd. (-0.03), greater than Immix Biopharma, Inc. (-2.41), greater than Hepion Pharmaceuticals, Inc. (-0.20), less than AVROBIO, Inc. (2.07), less than eFFECTOR Therapeutics, Inc. (-0.00),

Build a custom stock screener for Dermata Therapeutics, Inc. (DRMA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Dermata Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Dermata Therapeutics, Inc. (DRMA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Dermata Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.